Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, with chronic inflammation recognized as a critical factor in its pathogenesis. This review focuses on the roles of pro-inflammatory cytokines interleukin-6 (IL-6) and interleukin-17A (IL-17A), alongside the anti-inflammatory cytokine interleukin-10 (IL-10), in CRC development and progression. The reason we chose theese cytokines amoung others is that we found certain number of similar research in recent literature for comparision, condidering this topic is quite rare. Elevated levels of IL-6 and IL-17A have been linked to enhanced tumor proliferation, survival, invasion, and metastasis, highlighting their contribution to a tumor-promoting microenvironment. Conversely, IL-10 exhibits a dual role by suppressing inflammation yet potentially facilitating immune evasion and tumor progression in certain contexts. Understanding the complex interplay and signaling pathways of these cytokines may improve CRC risk assessment, diagnosis, prognosis, and offer new avenues for targeted therapies. This review synthesizes current evidence from recent literature to elucidate the molecular mechanisms and clinical implications of IL-6, IL-17A, and IL-10 in colorectal cancer.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.